公开(公告)号：EP0772594A1

公开(公告)日：1997-05-14

申请号：EP95926167.0

申请日：1995-06-28

申请人： Abbott Laboratories

发明人： BROOKS, Dee, W. ,  BHATIA, Pramila ,  KOLASA, Teodozyj ,  STEWART, Andrew, O.

IPC分类号： A61K31 ,  A61P11 ,  A61P17 ,  A61P19 ,  A61P27 ,  A61P43 ,  C07D213 ,  C07D215 ,  C07D235 ,  C07D239 ,  C07D241 ,  C07D263 ,  C07D277 ,  C07D401 ,  C07D405 ,  C07D409 ,  C07D413 ,  C07D417 ,  C07D513

CPC分类号： C07D213/30 ,  C07D215/14 ,  C07D215/227 ,  C07D215/36 ,  C07D235/12 ,  C07D239/26 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D513/04

摘要： The present invention relates to a compound of the formula: W-X-Q-Y-CH(R1)-O-N=C(R2)-A-COM, or a pharmaceutically acceptable salt thereof wherein W is optionally substituted aryl or heteroaryl; X is a valence bond, or methylene, divalent alkylene, alkenylene, alkynylene or alkyloxy; Q is a valence bond, or -O-, -S-, > NR4 or > NCOR5; Y is optionally substituted phenyl, biphenyl, naphthyl, tetrahydronaphthyl, indolyl, pyridyl, or benzo[b]thienyl, thienyl, thiazolyl, or thiazolylphenyl; R1 is alkyl, cycloalkyl, alkoxyalkyl, aryl or arylalkyl, heteroaryl or heteroarylalkyl; R2 is hydrogen, alkyl or hydroxyalkyl; A is a valence bond or is selected from alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, pyridylene, thienylene and furylene; and M is a pharmaceutically acceptable, metabolically cleavable group, -OR?6, -NR6R7¿, -NH-tetrazoyl, -NH-2-, 3-, or 4-pyridyl, and -NH-2-, 4-, or 5-thiazolyl which inhibit leukotriene biosynthesis and are useful in the treatment of inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method for inhibiting lipoxygenase activity and leukotriene biosynthesis.

公开(公告)号：EP0862557B1

公开(公告)日：2002-11-27

申请号：EP96932335.1

申请日：1996-09-25

申请人： Abbott Laboratories

发明人： BROOKS, Clint, D., W. ,  BHATIA, Pramila ,  KOLASA, Theodozyj ,  STEWART, Andrew, O. ,  GUNN, David, E. ,  CRAIG, Richard, A.

IPC分类号： C07D215/14 ,  A61K31/395 ,  C07D277/64 ,  C07D215/18 ,  C07D213/30 ,  C07D241/42 ,  C07D235/12

CPC分类号： C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D277/64

摘要： Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R?1 and R2¿ are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH¿2?-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR?6¿, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：EP1090009A2

公开(公告)日：2001-04-11

申请号：EP99926157.1

申请日：1999-06-03

申请人： ABBOTT LABORATORIES

发明人： STEWART, Andrew, O. ,  BOYD, Steven, A. ,  ARENDSEN, David, L. ,  BHATIA, Pramila ,  CONDROSKI, Kevin, R. ,  FREEMAN, Jennifer, C. ,  GUNAWARDANA, Indrani, W. ,  ZHU, Gui-Dong ,  LARTEY, Kraig ,  MCCARTY, Catherine, M. ,  MORT, Nicholas, A. ,  PATEL, Meena V. ,  STAEGER, Michael, A. ,  STOUT, David, M.

IPC分类号： C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D471/04 ,  C07D491/04 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505

CPC分类号： C07D471/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

摘要： Compounds having Formula (I) are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compouns of Formula (I), and methods of inhibiting/treating inflammatory diseases in a mammal.

摘要翻译： 具有式（I）的化合物可用于治疗炎症。 还公开了包含式（I）化合物的药物组合物，以及在哺乳动物中抑制/治疗炎性疾病的方法。

公开(公告)号：EP0667855A1

公开(公告)日：1995-08-23

申请号：EP94902209.0

申请日：1993-11-05

申请人： ABBOTT LABORATORIES

发明人： BASHA, Anwer ,  BHATIA, Pramila ,  BROOKS, Dee, W. ,  CRAIG, Richard, A. ,  RATAJCZYK, James, D. ,  STEWART, Andrew, O.

IPC分类号： A61K31 ,  A61P9 ,  A61P11 ,  A61P17 ,  A61P25 ,  A61P27 ,  A61P29 ,  A61P37 ,  A61P43 ,  C07C273 ,  C07C275 ,  C07D213 ,  C07D277 ,  C07D307 ,  C07D333 ,  C07D405 ,  C07D409 ,  C07D417

CPC分类号： C07D405/06 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D409/06

摘要： The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：EP1181296A1

公开(公告)日：2002-02-27

申请号：EP99931986.6

申请日：1999-06-28

申请人： ABBOTT LABORATORIES

发明人： ARENDSEN, David, L. ,  BHATIA, Pramila ,  BOYD, Steven, A. ,  CONDROSKI, Kevin, R. ,  FREEMAN, Jennifer, C. ,  GUNAWARDANA, Indrani, W. ,  LARTEY, Kraig ,  MCCARTY, Catherine, M. ,  MORT, Nicholas, A. ,  PATEL, Meena V. ,  STAEGER, Michael, A. ,  STEWART, Andrew, O. ,  STOUT, David, M. ,  ZHU, Gui-Dong

IPC分类号： C07D495/04

CPC分类号： C07D471/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

摘要： Compounds having formula (I) are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), and methods of inhibiting/treating inflammatory diseases in a mammal.

摘要翻译： 具有式（I）的化合物可用于治疗炎症。 还公开了包含式（I）化合物的药物组合物，以及在哺乳动物中抑制/治疗炎性疾病的方法。

公开(公告)号：EP0667855B1

公开(公告)日：1999-03-24

申请号：EP94902209.9

申请日：1993-11-05

申请人： ABBOTT LABORATORIES

发明人： BASHA, Anwer ,  BHATIA, Pramila ,  BROOKS, Dee, W. ,  CRAIG, Richard, A. ,  RATAJCZYK, James, D. ,  STEWART, Andrew, O.

IPC分类号： C07C275/20 ,  A61K31/17 ,  C07C275/64 ,  C07D307/52

CPC分类号： C07D405/06 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D409/06

摘要： The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

公开(公告)号：EP0862557A1

公开(公告)日：1998-09-09

申请号：EP96932335.0

申请日：1996-09-25

申请人： Abbott Laboratories

发明人： BROOKS, Clint, D., W. ,  BHATIA, Pramila ,  KOLASA, Theodozyj ,  STEWART, Andrew, O. ,  GUNN, David, E. ,  CRAIG, Richard, A.

IPC分类号： C07D239 ,  A61K31 ,  A61P37 ,  A61P43 ,  C07D213 ,  C07D215 ,  C07D235 ,  C07D241 ,  C07D263 ,  C07D277 ,  C07D417

CPC分类号： C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D277/64

摘要： Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R?1 and R2¿ are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH¿2?-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR?6¿, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.